I feel that an important point to be emphasized is that Dermicol-P35 is not readily modified after a relatively short period of time (less than one hour). This means that there is very little if any room for error when injecting the tear trough region with Dermicol-P35. This same argument can be applied to other fillers that cannot be easily modified well after injection. In my personal experience in treating this region, as well as my observations of patients treated by other excellent injectors, I have found that factors such as injection site swelling and bruising, injector judgment, exam room lighting, positioning of the patient's head, and a host of other factors can lead to the need for late postinjection modification of filler placed in the tear trough region. I therefore urge caution when using non-HA dermal fillers in the tear trough area.
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